R
Rhian Gabe
Researcher at Queen Mary University of London
Publications - 97
Citations - 5767
Rhian Gabe is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 26, co-authored 76 publications receiving 4543 citations. Previous affiliations of Rhian Gabe include University of York & University of London.
Papers
More filters
Journal ArticleDOI
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
Hashim U. Ahmed,Hashim U. Ahmed,Ahmed El-Shater Bosaily,Ahmed El-Shater Bosaily,Louise Brown,Rhian Gabe,Richard Kaplan,Mahesh K.B. Parmar,Yolanda Collaco-Moraes,Katie Ward,Richard Hindley,Alex Freeman,Alex Kirkham,Robert Oldroyd,Chris Parker,Mark Emberton,Mark Emberton +16 more
TL;DR: Using MP-MRI to triage men might allow 27% of patients avoid a primary biopsy and diagnosis of 5% fewer clinically insignificant cancers, as well as reduce unnecessary biopsies by a quarter.
Journal ArticleDOI
U.K. Controlled trial of intrapleural streptokinase for pleural infection.
Nick A Maskell,Christopher W. H. Davies,Andrew J. Nunn,Emma L. Hedley,Fergus V. Gleeson,Robert F. Miller,Rhian Gabe,Glyn L. Rees,Tim E. A. Peto,Mark A. Woodhead,Donald J. Lane,Janet Darbyshire,Robert J. O. Davies +12 more
TL;DR: The intrapleural administration of streptokinase does not improve mortality, the rate of surgery, or the length of the hospital stay among patients with pleural infection.
Journal ArticleDOI
The randomized trials of breast cancer screening: what have we learned?
Robert A. Smith,Stephen W. Duffy,Rhian Gabe,Laszlo Tabar,Amy Ming Fang Yen,Tony Hsiu Hsi Chen +5 more
TL;DR: The trials of mammographic screening provide conclusive evidence that the policy of offering screening is associated with a significant and substantial reduction in breast cancer mortality.
Journal ArticleDOI
Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214)
R. Timothy D. Oliver,Graham M. Mead,Gordon J. S. Rustin,Johnathan Joffe,Nina Aass,Robert E. Coleman,Rhian Gabe,Philip Pollock,Sally P. Stenning +8 more
TL;DR: These updated results confirm the noninferiority of single dose carboplatin (at 7 × AUC dose) versus RT in terms of RFR and establish a statistically significant reduction in the medium term of risk of second GCT produced by this treatment.
Journal ArticleDOI
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada,Sally P. Stenning,Rhian Gabe,L.C. Thompson,David Levy,R. Rampling,Sara Erridge,Frank Saran,Rao Gattamaneni,Kirsten Hopkins,Sarah Beall,V. Peter Collins,Siow-Ming Lee +12 more
TL;DR: Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5- day schedule in this setting, which challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.